Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)
ID: 357010Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357010

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-227.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)" aimed at expanding knowledge of disorders that are currently or may become part of statewide newborn screening programs. This initiative seeks to gather comprehensive data on the natural history of these conditions to facilitate appropriate interventions for affected infants, improve diagnostic accuracy, and support the development of targeted treatments. The funding will assist in identifying biological mechanisms, understanding genetic diversity, and establishing data collection systems for longitudinal studies, emphasizing the importance of research in newborn screening. Interested applicants, including various educational and community organizations, can submit proposals with a maximum project period of five years, with the funding cycle opening on January 5, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-227.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-227-Full-Announcement.html
    PAR-25-227.html
    The Department of Health and Human Services announces a funding opportunity through the National Institutes of Health (NIH) for research projects focused on understanding the natural history of disorders that are or may be included in newborn screening programs. The goal is to gather comprehensive knowledge about conditions detectable at birth to support appropriate interventions for affected infants. The funding will assist in identifying biological mechanisms, understanding genetic diversity, improving diagnosis, and establishing data collection systems for longitudinal studies. Applications are encouraged from various organizations, including higher education institutions and non-profits, with budgets reflecting the proposed project's actual needs. The number of awards will depend on NIH appropriations and meritorious application submissions. The funding cycle opens on January 5, 2025, with a maximum project period of five years. This initiative underscores the ongoing need for expanded research in newborn screening to develop better treatments and interventions, bridging existing gaps in disease progression knowledge.
    Similar Opportunities
    Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research into the natural history of disorders detectable through newborn screening, under the grant title "Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)." This initiative aims to enhance understanding of these disorders to support early identification and intervention, focusing on improving diagnostic accuracy, elucidating genetic and clinical heterogeneity, and exploring underlying mechanisms to inform treatment options. The funding is available for new, renewal, resubmission, or revision applications, with a maximum support period of five years and no cost-sharing requirement. Interested applicants, including various educational and community organizations, must submit proposals by January 7, 2025, and can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance or further information.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R03 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at encouraging research into novel screening methods and therapeutic interventions for serious genetic and congenital conditions identified through newborn screening. This initiative, under the R03 Small Grant Program, supports small-scale projects lasting up to two years with a budget of up to $50,000 per year, focusing on developing robust screening technologies to enhance early detection and treatment of disorders, thereby minimizing long-term health consequences. The program is particularly important for addressing high-priority conditions where screening is not currently recommended, and it emphasizes inclusivity in research by inviting applications from a diverse range of organizations, including higher education institutions and community-based organizations. Interested applicants should note that the application deadline is November 16, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for innovative research aimed at developing screening approaches and therapies for screenable disorders in newborns, designated as R21 - Clinical Trial Optional. This initiative encourages projects that focus on creating novel screening techniques and therapeutic interventions for potentially fatal or disabling conditions identified through newborn screening, particularly emphasizing early diagnosis and treatment to improve health outcomes. The program is part of NIH's commitment to advancing public health and reducing health disparities, with a funding ceiling of $275,000 available over a two-year period. Interested applicants, including a diverse range of institutions and organizations, must submit their proposals by November 16, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)" aimed at advancing research on congenital defects linked to genetic variants. This initiative encourages the use of cutting-edge genotyping and sequencing technologies to validate genetic variants identified through public databases, bridging the gap between variant identification and understanding their functional impacts on developmental outcomes. The funding is available to a diverse range of eligible organizations, including higher education institutions and nonprofits, with an annual budget cap of $499,999 and a project period of up to five years. Interested applicants should contact the NIH OER Webmaster at grantsinfo@nih.gov for assistance and must submit their proposals by May 7, 2025, to be considered for this significant funding opportunity.
    Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research into the mechanisms underlying structural birth defects. This grant encourages applicants to utilize animal models alongside human translational and clinical approaches, focusing on genetic, epigenetic, and environmental factors that contribute to these conditions. With over 120,000 infants affected annually in the U.S., this research is critical for public health, and projects may receive funding of up to $499,999 per year for a maximum of five years. Interested applicants must submit their proposals by September 7, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details at https://grants.nih.gov/grants/guide/pa-files/PAR-22-215.html.
    Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research into the mechanisms underlying structural birth defects. This initiative encourages applicants to utilize advancements in genetics, omics methods, and synthetic biology to explore genetic, environmental, and epigenetic factors contributing to these anomalies, which affect approximately 3% of live births in the U.S. The grant allows for budgets up to $499,999 in direct costs per year, with project periods not exceeding five years, and applications are due by February 5, 2025. Interested parties can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Screening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the screening and functional validation of genomic variants associated with human congenital anomalies through the R01 Clinical Trial Not Allowed grant. This initiative aims to leverage advancements in genomic technologies to identify and validate genetic variants linked to congenital defects, intellectual developmental disabilities, and inborn errors of metabolism, thereby bridging the gap between genetic identification and functional impact on health. Eligible applicants include a wide range of institutions such as universities, nonprofits, and tribal governments, with a maximum budget of $499,999 per project year and a project duration of up to five years. Interested parties should submit their applications by January 7, 2028, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-185.html for further details.
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)." This initiative aims to support the clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders, focusing on establishing their clinical sensitivity and specificity in accordance with FDA guidelines. The program is particularly significant as it seeks to enhance public health outcomes by facilitating the implementation of validated biomarkers in clinical settings, thereby addressing critical healthcare needs in these areas. Interested applicants should note that the application period opens on January 21, 2025, and closes on June 22, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-055.html.
    Research Project Grant (Parent R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Research Project Grant (Parent R01 Clinical Trial Required) to support specified clinical research projects that align with the missions of various NIH institutes. Applicants are required to propose at least one clinical trial, focusing on significant health-related research areas, and must comply with the NIH Grants Policy Statement. This funding opportunity is crucial for advancing medical science and improving patient care, emphasizing innovation and scientific merit in addressing important health issues. The application deadline is January 7, 2025, and interested parties can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further inquiries. More details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PA-20-183.html.
    SBIR Solutions to Enable Population Genomic Screening (R43/R44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "SBIR Solutions to Enable Population Genomic Screening," aimed at soliciting Small Business Innovation Research (SBIR) grant applications from U.S. small businesses. The objective of this initiative is to develop innovative solutions that facilitate population genomic screening for common, actionable genomic conditions within primary care settings, addressing significant barriers such as logistical challenges, provider education, and follow-up procedures. This program is crucial for enhancing the readiness of primary care providers to manage genomic screening, particularly for conditions like hereditary breast cancer and Lynch syndrome. Grants of up to $400,000 are available for Phase I applications, with Phase II grants potentially reaching $2.15 million. Interested applicants should note that the submission window opens on November 1, 2024, with a deadline for applications set for December 2, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.